BNTC Benitec Biopharma Inc Projected Price to Earnings
This price action chart on GURU.Markets shows a P/E ratio of 0.00. Benitec Biopharma Inc. (BNTC) is attracting leading genetics specialists by offering them stock options and the opportunity to shape the future of medicine. The company focuses on developing gene silencing methods, though it is currently unprofitable as its products undergo FDA review and the cost of therapy will be determined upon completion of testing.
Financial and market metric breakdowns for Benitec Biopharma Inc. (BNTC)
- stock quotes and analyst forecast:
- market capitalization data:
- issuer book value statistics:
- debt and solvency information:
Total Debt to Equity Ratio Benitec Biopharma Inc.|BNTC - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Benitec Biopharma|BNTC - Company Debts|Debts to Book Capitalization Benitec Biopharma Inc.|BNTC - Long-Term Debt Volume|Company Short-Term Debt Benitec Biopharma|Quick Liquidity benitec.com
- earnings and market ratios statistics:
BNTC - Profit After Tax|Projected Future Earnings Benitec Biopharma Inc.|BNTC - Company Value to Net Income|Forward P/E Multiple Benitec Corp|BNTC - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Benitec Biopharma|BNTC - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Benitec Biopharma|BNTC - Net earnings per share for the last 12 months|Quarterly EPS earnings growth benitec.com|BNTC - Earnings growth in current year|Expected earnings per share growth for next year Benitec Biopharma Inc.
- sales and revenue data:
General company analysis:Benitec Corp
The specifics of Benitec Biopharma Inc. (BNTC) gene therapy development are associated with high toxicity risks and a liquidity deficit. The forward P/E reflects the ratio of the business's market value to projected net income. By analyzing the company's consensus P/E forecast, an investor assesses the extent to which expectations for future earnings are inflated. The indicator's trend reveals asset overvaluation amid volatility in the biotechnology sector. This tool characterizes the securities as a high-risk speculative asset.
Main competitors
Projected Price to Earnings TEM (Tempus AI, Inc)|Qiagen Group (QGEN) - Forward Price to Earnings Multiple|Future Price to Earnings ionispharma.com IONS|Market Cap to Projected Earnings Repligen Corporation (RGEN)|RNA: Projected Price to Earnings|Future Price to Earnings Multiple CRSP (CRISPR Therapeutics Corp)|WGS: Forward P/E Multiple|Projected Price to Earnings Ratio Ultragenyx Corp (RARE)|BEAM (Beam Therapeutics Inc) - Forward P/E Multiple|SRPT: Future Price to Earnings Multiple|Future Price to Earnings Twist Bioscience Corp (TWST)|Projected Price to Earnings 10x Genomics Inc TXG|Intellia Therapeutics, Inc. - Projected Price to Earnings|Future Price to Earnings Multiple STOK|BLFS - Future Price to Earnings|Wave Life Sciences (WVE) - Projected Price to Earnings|MAZE: Forward P/E Multiple|Sionna Therapeutics, Inc. (SION) - Forward P/E Multiple|Future Price to Earnings Prime Medicine, Inc.|TSHA (Taysha) - Market Cap to Future Earnings Ratio|Projected Price to Earnings QURE (uniQure Pharma)|Market Cap to Projected Earnings meiragtx.com|Future Price to Earnings REGENXBIO RGNX|SLDB - Projected Price to Earnings|Ocugen, Inc. - Forward P/E Multiple|PACB (Pacific Biosciences of California) - Price to Future Earnings Ratio|DSGN: Forward P/E Multiple|RCKT: Market Cap to Future Earnings Ratio|FDMT (4D Molecular Therapeutics, Inc.) - Forward P/E Multiple|lexeotx.com (LXEO) - Market Cap to Projected Earnings|Forward P/E Multiple KRRO|Projected Price to Earnings Editas Medicine, Inc. EDIT|Future Price to Earnings silence-therapeutics.com SLN|PRQR: Price to Future Earnings Ratio|CDXS - Future Price to Earnings|Market Cap to Projected Earnings Sangamo Therapeutics, Inc. SGMO|NAUT (nautilus.bio) - Projected Price to Earnings|Projected Price to Earnings Ratio Metagenomi, Inc. (MGX)|Projected Price to Earnings DTIL|Price to Future Earnings Ratio GBIO (generationbio.com)|Future Price to Earnings Boundless Bio, Inc (BOLD)|Forward P/E Multiple Exicure Inc. (XCUR)|Imunon, Inc. - Projected Price to Earnings|PHIO: Price to Future Earnings Ratio|MBIO - Future Price to Earnings|Price to Expected Earnings Ratio RNAZ|Bionano Genomics, Inc. (BNGO) - Future Price to Earnings|Applied DNA Sciences, Inc. (APDN) - Forward P/E Multiple|BLUE (bluebirdbio.com) - Forward P/E Multiple|Price to Future Earnings Ratio IPA (ImmunoPrecise Antibodies)|Forward P/E Multiple OMGA|Projected Price to Earnings Singular Genomics Systems OMIC|Forward P/E Multiple RGLS (regulusrx.com)|Syros Pharmaceuticals Inc. (SYRS) - Projected Price to Earnings Ratio|TBIO: Projected Price to Earnings|Future Price to Earnings Multiple TCON (TRACON)|UBX: Forward P/E Multiple
